Efficacies of Susceptibility-guided vs Empiric Therapy for Rescue Treatment of Helicobacter Pylori Infection

PHASE4RecruitingINTERVENTIONAL
Enrollment

450

Participants

Timeline

Start Date

April 11, 2022

Primary Completion Date

September 30, 2025

Study Completion Date

December 31, 2025

Conditions
Helicobacter Pylori Infection
Interventions
DRUG

susceptibility-guided tailored therapy (Group A)

"Includes 5 treatment options. The priority order of treatment regimens is based on the selection principal through AST with MIC profile.~1\. clarithromycin triple therapy: include rabeprazole 20mg bid, amoxicillin 1 g bid, and clarithromycin 500 mg bid, for 14 days; or 2. levofloxacin triple therapy: include rapeprazole 20 mg bid, amoxicillin 1 g bid, and levofloxacin 500 mg bid, for 14 days; or 3. metronidazole triple therapy: include rabeprazole 20 mg bid, amoxicillin 500 mg qid, and metronidazole 250 mg qid, for 14 days; or 4. high-dose dual therapy: include rabeprazole 20 mg qid, amoxicillin 750 mg qid, for 14 days; or 5. bismuth quadruple therapy: include rabeprazole 20 mg bid, bismuth 120 mg qid, metronidazole 500 mg tid, and tetracycline 500 mg qid, for 14 days."

DRUG

guidelines-recommended empiric therapy (Group B)

bismuth quadruple therapy: include rabeprazole 20 mg bid, bismuth 120 mg qid, metronidazole 500 mg tid, and tetracycline 500 mg qid, for 14 days.

Trial Locations (1)

Unknown

RECRUITING

National Taiwan University Hospital, Taipei

All Listed Sponsors
lead

National Taiwan University Hospital

OTHER